Drugs Made in America Acquisition Corp. (NASDAQ:DMAAU – Get Free Report) traded down 1.9% during trading on Tuesday . The stock traded as low as $10.69 and last traded at $10.69. 3,384 shares were traded during mid-day trading, a decline of 55% from the average session volume of 7,557 shares. The stock had previously closed at $10.90.
Drugs Made in America Acquisition Price Performance
The company’s fifty day moving average price is $10.59 and its 200 day moving average price is $10.54.
About Drugs Made in America Acquisition
Drugs Made in America Acquisition Corp is a special purpose acquisition company incorporated in Delaware and traded on the NASDAQ under the ticker DMAAU. It was organized to raise capital through its initial public offering and to identify and complete a business combination with one or more U.S.-based pharmaceutical or biotechnology companies.
The company’s investment mandate is focused on target businesses engaged in the development, manufacture or commercialization of finished dosage pharmaceuticals, active pharmaceutical ingredients and related medical products for the American market.
See Also
- Five stocks we like better than Drugs Made in America Acquisition
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Receive News & Ratings for Drugs Made in America Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made in America Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
